Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials
British Journal of Dermatology · 2026
DOI: 10.1093/bjd/ljaf309 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Kristian Reich und 14 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Ha…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Manchester Biomedical Research Centre.
Abstract (Originalsprache)
Background
Patients with moderate-to-severe atopic dermatitis (AD) require long-term management. Understanding the long-term safety of new treatments is a top priority for patients and healthcare professionals.
Objectives
To evaluate the safety of tralokinumab in adults and adolescents with moderate-to-severe AD by conducting an integrated safety analysis of seven placebo-controlled trials and the ongoing, open-label extension study ECZTEND (NCT03587805).
Methods
An initial 16-week placebo-controlled (PBO-CTRL) safety set and an all-tralokinumab (ALL-TRALO) safety set combining the placebo-controlled trials and ECZTEND (data cutoff 30 April 2022) were analysed. All treatment-emergent adverse events were recorded. Adverse events of special interest (AESIs) were predefined. Safety areas of clinical interest for advanced systemic AD treatments were captured retrospectively. Proportions of patients with events and incidence rates (IRs) per 100 patient-years of exposure (PYE) were calculated. PYE was defined as the time until the first event or exposure end, whichever came first, and incidence was defined as the first event.
Results
Safety results were similar between the PBO-CTRL safety set and ALL-TRALO safety set. In the latter, 2693 patients received tralokinumab for up to 238.5 weeks (approximately 4.5 years, PYE = 5320.2). Most adverse events (AEs) were nonserious, mild or moderate in severity, and occurred with similar frequencies between tralokinumab and placebo in the PBO-CTRL safety set. The most common AEs that occurred at higher rates for tralokinumab vs. placebo were nasopharyngitis [IR ratio (IRR) comparing tralokinumab vs. placebo 1.26], conjunctivitis (IRR 3.11) and injection site reaction (IRR 19.57). Dermatitis atopic and asthma occurred at lower rates with tralokinumab vs. placebo (IRR 0.51 and IRR 0.57, respectively). AESI eye disorders occurred at higher rates with tralokinumab vs. placebo (IRR 2.43) and 98% were mild to moderate. AESIs that were less frequent with tralokinumab vs. placebo included skin infections requiring systemic treatment (IRR 0.43) and eczema herpeticum (IRR 0.32). Rates of AEs of clinical interest (related to other approved systemic AD treatments) were low and similar between treatment groups. IRs of AEs did not increase with longer exposure in the ALL-TRALO safety set.
Conclusions
Long-term use of tralokinumab in adults and adolescents with moderate-to-severe AD was well-tolerated and consistent with the initial placebo-controlled treatment period, with no new safety signals identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, NS, Canada.
- Dermatology Department, Hospital General Universitario Dr Balmis, ISABIAL, Alicante, Spain.
- Department of Dermatology, University Hospital of Lille, INFINITE (Institute for Translational Research) U1286 Inserm, University of Lille, Lille, France.
- Dermatology Unit Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milan, Italy.
ORCID-Profile: Kristian Reich, Richard G Langley, Juan Francisco Silvestre Salvador, Delphine Staumont-Sallé, Antonio Costanzo, Andrew E Pink, Amy S Paller, Norito Katoh, Andreas Wollenberg, Richard B Warren, Andrew Blauvelt, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum
Förderung
- NIHR Manchester Biomedical Research Centre
Zitieren
APA
Reich, K., Langley, R. G., Silvestre Salvador, J. F., Staumont-Sallé, D., Costanzo, A., Pink, A. E., Paller, A. S., Katoh, N., Wollenberg, A., Warren, R. B., Blauvelt, A., Bjerregård Øland, C., Tindberg, A. M., Gjerum, L., & Simpson, E. L. (2026). Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf309
Vancouver
Reich K, Langley RG, Silvestre Salvador JF, Staumont-Sallé D, Costanzo A, Pink AE, et al. Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljaf309
BibTeX
@article{Reich2026,
author = {Reich, Kristian and Langley, Richard G and Silvestre Salvador, Juan Francisco and Staumont-Sallé, Delphine and Costanzo, Antonio and Pink, Andrew E and Paller, Amy S and Katoh, Norito and Wollenberg, Andreas and Warren, Richard B and Blauvelt, Andrew and Bjerregård Øland, Christian and Tindberg, Ann-Marie and Gjerum, Le and Simpson, Eric L},
title = {Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljaf309}
}
EUVIMED